Mitchell Jones

Dr. Mitchell Jones is the Chief Medical Officer at Palisade Bio (NASDAQ: PALI), a clinical-stage biopharmaceutical company advancing precision therapies for immune, inflammatory, and fibrotic diseases. He leads the development of PALI-2108, a dual-acting anti-inflammatory and anti-fibrotic PDE4 inhibitor prodrug targeting the terminal ileum and colon for ulcerative colitis and fibrostenotic Crohn’s disease. With over 18 years of experience in translational science and biotechnology, Dr. Jones has advanced multiple GI therapies from concept to clinic. He previously held senior roles at Chemomab, Biora, and Finch Therapeutics, and earned his MD, PhD, and MS from McGill University.

At the 4th Precision Medicine in IBD Summit, Dr. Jones will present “Targeted PDE4 Inhibition Using PALI-2108 Prodrug as a Novel Therapeutic Strategy in Fibrostenotic Crohn’s Disease”, highlighting how gut-restricted pharmacology and translational biomarker science are converging to redefine the treatment of fibrostenotic IBD.